Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism.

Welters A, Meissner T, Grulich-Henn J, Fröhlich-Reiterer E, Warncke K, Mohnike K, Blankenstein O, Menzel U, Datz N, Bollow E, Holl RW.

Orphanet J Rare Dis. 2018 Dec 22;13(1):230. doi: 10.1186/s13023-018-0970-8.

2.

Newborn screening by tandem mass spectrometry confirms the high prevalence of sickle cell disease among German newborns.

Lobitz S, Klein J, Brose A, Blankenstein O, Frömmel C.

Ann Hematol. 2019 Jan;98(1):47-53. doi: 10.1007/s00277-018-3477-4. Epub 2018 Aug 21.

PMID:
30132072
3.

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.

Clément K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, Puder L, Fiedorek F, Gottesdiener K, Kleinau G, Heyder N, Scheerer P, Blume-Peytavi U, Jahnke I, Sharma S, Mokrosinski J, Wiegand S, Müller A, Weiß K, Mai K, Spranger J, Grüters A, Blankenstein O, Krude H, Kühnen P.

Nat Med. 2018 May;24(5):551-555. doi: 10.1038/s41591-018-0015-9. Epub 2018 May 7.

PMID:
29736023
4.

Mean High-Dose l-Thyroxine Treatment Is Efficient and Safe to Achieve a Normal IQ in Young Adult Patients With Congenital Hypothyroidism.

Aleksander PE, Brückner-Spieler M, Stoehr AM, Lankes E, Kühnen P, Schnabel D, Ernert A, Stäblein W, Craig ME, Blankenstein O, Grüters A, Krude H.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1459-1469. doi: 10.1210/jc.2017-01937.

PMID:
29325045
5.

Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome.

Plöckinger U, Chrusciel M, Doroszko M, Saeger W, Blankenstein O, Weizsäcker K, Kroiss M, Hauptmann K, Radke C, Pöllinger A, Tiling N, Steinmüller T, Huhtaniemi I, Quinkler M, Bertherat J, Lacroix A, Rahman N.

J Endocr Soc. 2017 Jan 12;1(1):57-71. doi: 10.1210/js.2016-1021. eCollection 2017 Jan 1.

6.

Primary sulphonylurea therapy in a newborn with transient neonatal diabetes attributable to a paternal uniparental disomy 6q24 (UPD6).

Neumann U, Bührer C, Blankenstein O, Kühnen P, Raile K.

Diabetes Obes Metab. 2018 Feb;20(2):474-475. doi: 10.1111/dom.13085. Epub 2017 Oct 5. No abstract available.

PMID:
28817249
7.

Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency.

Neumann U, Whitaker MJ, Wiegand S, Krude H, Porter J, Davies M, Digweed D, Voet B, Ross RJ, Blankenstein O.

Clin Endocrinol (Oxf). 2018 Jan;88(1):21-29. doi: 10.1111/cen.13447. Epub 2017 Sep 7.

8.

Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study.

Blankenstein O, Snajderova M, Blair J, Pournara E, Pedersen BT, Petit IO.

Eur J Endocrinol. 2017 Aug;177(2):145-155. doi: 10.1530/EJE-16-1055. Epub 2017 May 18.

9.

Quality of compounded hydrocortisone capsules used in the treatment of children.

Neumann U, Burau D, Spielmann S, Whitaker MJ, Ross RJ, Kloft C, Blankenstein O.

Eur J Endocrinol. 2017 Aug;177(2):239-242. doi: 10.1530/EJE-17-0248. Epub 2017 May 16.

10.

Somatic mutations and progressive monosomy modify SAMD9-related phenotypes in humans.

Buonocore F, Kühnen P, Suntharalingham JP, Del Valle I, Digweed M, Stachelscheid H, Khajavi N, Didi M, Brady AF, Blankenstein O, Procter AM, Dimitri P, Wales JKH, Ghirri P, Knöbl D, Strahm B, Erlacher M, Wlodarski MW, Chen W, Kokai GK, Anderson G, Morrogh D, Moulding DA, McKee SA, Niemeyer CM, Grüters A, Achermann JC.

J Clin Invest. 2017 May 1;127(5):1700-1713. doi: 10.1172/JCI91913. Epub 2017 Mar 27.

11.

Is safety of childhood growth hormone therapy related to dose? Data from a large observational study.

Sävendahl L, Pournara E, Pedersen BT, Blankenstein O.

Eur J Endocrinol. 2017 Mar;176(3):X1. doi: 10.1530/EJE-15-1017e. No abstract available.

PMID:
28159881
12.

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Grüters A, Krude H.

N Engl J Med. 2016 Jul 21;375(3):240-6. doi: 10.1056/NEJMoa1512693.

13.

Positive correlation of thyroid hormones and serum copper in children with congenital hypothyroidism.

Blasig S, Kühnen P, Schuette A, Blankenstein O, Mittag J, Schomburg L.

J Trace Elem Med Biol. 2016 Sep;37:90-95. doi: 10.1016/j.jtemb.2016.05.007. Epub 2016 May 24.

PMID:
27267969
14.

Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study.

Prasad V, Sainz-Esteban A, Arsenic R, Plöckinger U, Denecke T, Pape UF, Pascher A, Kühnen P, Pavel M, Blankenstein O.

Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1593-600. doi: 10.1007/s00259-016-3331-7. Epub 2016 Feb 29.

PMID:
26923247
15.

Is safety of childhood growth hormone therapy related to dose? Data from a large observational study.

Sävendahl L, Pournara E, Pedersen BT, Blankenstein O.

Eur J Endocrinol. 2016 May;174(5):681-91. doi: 10.1530/EJE-15-1017. Epub 2016 Feb 22.

PMID:
26903552
16.

Congenital Adrenal Hyperplasia with Non-functional Mutations in Both Alleles in a Clinically Unaffected Infant.

Hoehn T, Lukacs Z, Huckenbeck W, Torresani T, Blankenstein O, Bounnack S.

J Trop Pediatr. 2016 Apr;62(2):158-60. doi: 10.1093/tropej/fmv078. Epub 2015 Dec 31.

17.

Normative Thyroid-Stimulating Hormone Values for Healthy Nigerian Newborns.

Yarhere IE, Jaja T, Oduwole A, Ibekwe MU, Suwaid S, Alkali Y, Adeniran K, Fetuga B, Jarrett OO, Elusiyan JB, Adesiyun O, Idris HW, Blankenstein O, Akani NA.

Horm Res Paediatr. 2016;85(1):22-8. doi: 10.1159/000441722. Epub 2015 Dec 16.

PMID:
26670140
18.

Development and testing in healthy adults of oral hydrocortisone granules with taste masking for the treatment of neonates and infants with adrenal insufficiency.

Whitaker MJ, Spielmann S, Digweed D, Huatan H, Eckland D, Johnson TN, Tucker G, Krude H, Blankenstein O, Ross RJ.

J Clin Endocrinol Metab. 2015 Apr;100(4):1681-8. doi: 10.1210/jc.2014-4060. Epub 2015 Feb 3.

PMID:
25646792
19.

Management and interpretation of heterogeneous observational data: using insulin-like growth factor-I data from the NordiNet® International Outcome Study.

Blankenstein O, Pedersen BT, Schlumpf M, Andreasen AH, Júlíusson PB.

Growth Horm IGF Res. 2015 Feb;25(1):41-6. doi: 10.1016/j.ghir.2014.12.001. Epub 2014 Dec 9.

20.

[Newborn screening: a prime example for effective secondary prevention].

Nennstiel-Ratzel U, Lüders A, Blankenstein O.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Feb;58(2):139-45. doi: 10.1007/s00103-014-2092-3. German.

PMID:
25475525
21.

Hydrocortisone replacement in disorders of sex development.

Blankenstein O.

Endocr Dev. 2014;27:160-71. doi: 10.1159/000363752. Epub 2014 Sep 9. Review.

PMID:
25247653
22.

Newborn screening for sickle cell disease: technical and legal aspects of a German pilot study with 38,220 participants.

Frömmel C, Brose A, Klein J, Blankenstein O, Lobitz S.

Biomed Res Int. 2014;2014:695828. doi: 10.1155/2014/695828. Epub 2014 Jul 23.

23.

Occurrence of giant focal forms of congenital hyperinsulinism with incorrect visualization by (18) F DOPA-PET/CT scanning.

Kühnen P, Matthae R, Arya V, Hauptmann K, Rothe K, Wächter S, Singer M, Mohnike W, Eberhard T, Raile K, Lauffer LM, Iakoubov R, Hussain K, Blankenstein O.

Clin Endocrinol (Oxf). 2014 Dec;81(6):847-54. doi: 10.1111/cen.12473. Epub 2014 May 19.

PMID:
24750227
24.

Hyperinsulinaemic hypoglycaemia.

Arya VB, Mohammed Z, Blankenstein O, De Lonlay P, Hussain K.

Horm Metab Res. 2014 Mar;46(3):157-70. doi: 10.1055/s-0034-1367063. Epub 2014 Feb 20. Review.

PMID:
24557504
25.

Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany.

Lobitz S, Frömmel C, Brose A, Klein J, Blankenstein O.

Eur J Hum Genet. 2014 Aug;22(8):1051-3. doi: 10.1038/ejhg.2013.286. Epub 2014 Jan 8.

26.

Two novel GATA6 mutations cause childhood-onset diabetes mellitus, pancreas malformation and congenital heart disease.

Gong M, Simaite D, Kühnen P, Heldmann M, Spagnoli F, Blankenstein O, Hübner N, Hussain K, Raile K.

Horm Res Paediatr. 2013;79(4):250-6. doi: 10.1159/000348844. Epub 2013 Apr 26.

PMID:
23635550
27.

[Status quo of children's preventative medicine programmes--results of the first German nationwide workshop 2011 in Frankfurt am Main].

Hock S, Berchner Y, Blankenstein O, Buschbaum T, Ellsässer G, Heuermann MW, Klein R, Kolbow D, Metzner F, Röhlich-Pause K, Thaiss H, Untze P, Zimmermann E, Kieslich M.

Gesundheitswesen. 2013 Mar;75(3):143-8. doi: 10.1055/s-0032-1331731. Epub 2013 Jan 29. German.

PMID:
23361405
28.

Long-term lanreotide treatment in six patients with congenital hyperinsulinism.

Kühnen P, Marquard J, Ernert A, Meissner T, Raile K, Wannenmacher G, Blankenstein O.

Horm Res Paediatr. 2012;78(2):106-12. Epub 2012 Aug 14.

PMID:
22907123
29.

Comparison of response to 2-years' growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies.

Lee PA, Sävendahl L, Oliver I, Tauber M, Blankenstein O, Ross J, Snajderova M, Rakov V, Pedersen BT, Christesen HT.

Int J Pediatr Endocrinol. 2012 Jul 12;2012(1):22. doi: 10.1186/1687-9856-2012-22.

30.

Gender influences short-term growth hormone treatment response in children.

Sävendahl L, Blankenstein O, Oliver I, Christesen HT, Lee P, Pedersen BT, Rakov V, Ross J.

Horm Res Paediatr. 2012;77(3):188-94. doi: 10.1159/000337570. Epub 2012 Apr 12.

PMID:
22508317
31.

Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis?

Hoefig CS, Renko K, Piehl S, Scanlan TS, Bertoldi M, Opladen T, Hoffmann GF, Klein J, Blankenstein O, Schweizer U, Köhrle J.

Mol Cell Endocrinol. 2012 Feb 26;349(2):195-201. doi: 10.1016/j.mce.2011.10.024. Epub 2011 Oct 28.

PMID:
22061622
32.

The heterogeneity of focal forms of congenital hyperinsulinism.

Ismail D, Kapoor RR, Smith VV, Ashworth M, Blankenstein O, Pierro A, Flanagan SE, Ellard S, Hussain K.

J Clin Endocrinol Metab. 2012 Jan;97(1):E94-9. doi: 10.1210/jc.2011-1628. Epub 2011 Oct 26.

PMID:
22031516
33.

Harmonization of growth hormone measurements with different immunoassays by data adjustment.

Müller A, Scholz M, Blankenstein O, Binder G, Pfäffle R, Körner A, Kiess W, Heider A, Bidlingmaier M, Thiery J, Kratzsch J.

Clin Chem Lab Med. 2011 Jul;49(7):1135-42. doi: 10.1515/CCLM.2011.201. Epub 2011 Jun 1.

PMID:
21627539
34.

Diabetes caused by insulin gene (INS) deletion: clinical characteristics of homozygous and heterozygous individuals.

Raile K, O'Connell M, Galler A, Werther G, Kühnen P, Krude H, Blankenstein O.

Eur J Endocrinol. 2011 Aug;165(2):255-60. doi: 10.1530/EJE-11-0208. Epub 2011 May 12.

PMID:
21566073
35.

Intraoperative sonography: a technique for localizing focal forms of congenital hyperinsulinism in the pancreas.

von Rohden L, Mohnike K, Mau H, Eberhard T, Mohnike W, Blankenstein O, Empting S, Koch M, Füchtner F, Barthlen W.

Ultraschall Med. 2011 Feb;32(1):74-80. doi: 10.1055/s-0029-1245598. Epub 2011 Feb 8.

PMID:
21305438
36.

The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy.

Zani A, Nah SA, Ron O, Totonelli G, Ismail D, Smith VV, Ashworth M, Blankenstein O, Mohnike W, De Coppi P, Eaton S, Hussain K, Pierro A.

J Pediatr Surg. 2011 Jan;46(1):204-8. doi: 10.1016/j.jpedsurg.2010.09.093.

PMID:
21238668
37.

Visualization of the focus in congenital hyperinsulinism by intraoperative sonography.

von Rohden L, Mohnike K, Mau H, Eberhard T, Mohnike W, Blankenstein O, Empting S, Koch M, Füchtner F, Barthlen W.

Semin Pediatr Surg. 2011 Feb;20(1):28-31. doi: 10.1053/j.sempedsurg.2010.10.011.

PMID:
21186001
38.

Positron emission tomography/computed tomography diagnostics by means of fluorine-18-L-dihydroxyphenylalanine in congenital hyperinsulinism.

Mohnike W, Barthlen W, Mohnike K, Blankenstein O.

Semin Pediatr Surg. 2011 Feb;20(1):23-7. doi: 10.1053/j.sempedsurg.2010.10.007.

PMID:
21186000
39.

Familial focal congenital hyperinsulinism.

Ismail D, Smith VV, de Lonlay P, Ribeiro MJ, Rahier J, Blankenstein O, Flanagan SE, Bellanné-Chantelot C, Verkarre V, Aigrain Y, Pierro A, Ellard S, Hussain K.

J Clin Endocrinol Metab. 2011 Jan;96(1):24-8. doi: 10.1210/jc.2010-1524. Epub 2010 Oct 13.

40.

Treating patients not numbers: the benefit and burden of lowering TSH newborn screening cut-offs.

Krude H, Blankenstein O.

Arch Dis Child. 2011 Feb;96(2):121-2. doi: 10.1136/adc.2009.174466. Epub 2010 Jul 6. No abstract available.

PMID:
20605867
41.

Congenital hyperinsulinism.

Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K, Valayannopoulos V, Robert JJ, Rahier J, Sempoux C, Bellanné C, Verkarre V, Aigrain Y, Jaubert F, Brunelle F, Nihoul-Fékété C.

Early Hum Dev. 2010 May;86(5):287-94. doi: 10.1016/j.earlhumdev.2010.05.003. Epub 2010 Jun 13. Review.

PMID:
20550977
42.

Congenital hyperinsulinism: [F]DOPA PET/CT scan of a focal lesion in the head of the pancreas.

Kapoor RR, Gilbert C, Mohnike K, Blankenstein O, Fuechtner F, Hussain K.

BMJ Case Rep. 2009;2009:bcr2007121178. doi: 10.1136/bcr.2007.121178. Epub 2009 Feb 16. No abstract available.

43.

[Sedation of infants with congenital hyperinsulinism during PET CAT scanning. A case collection].

Kork F, Blankenstein O, Mohnike W, Höhne C.

Anaesthesist. 2008 Nov;57(11):1087-90. doi: 10.1007/s00101-008-1423-x. German.

PMID:
18726079
44.

[18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism.

Mohnike K, Blankenstein O, Minn H, Mohnike W, Fuchtner F, Otonkoski T.

Horm Res. 2008;70(2):65-72. doi: 10.1159/000137655. Epub 2008 Jun 12. Review.

45.

Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.

Mohnike K, Blankenstein O, Pfuetzner A, Pötzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM.

Horm Res. 2008;70(1):59-64. doi: 10.1159/000129680. Epub 2008 May 21.

PMID:
18493152
46.

EDTA in dried blood spots leads to false results in neonatal endocrinologic screening.

Holtkamp U, Klein J, Sander J, Peter M, Janzen N, Steuerwald U, Blankenstein O.

Clin Chem. 2008 Mar;54(3):602-5. doi: 10.1373/clinchem.2007.096685.

47.

Congenital hyperinsulinism: [18F]DOPA PET/CT scan of a focal lesion in the head of the pancreas.

Kapoor RR, Gilbert C, Mohnike K, Blankenstein O, Fuechtner F, Hussain K.

Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F166. doi: 10.1136/adc.2007.121178. No abstract available.

PMID:
18296575
48.

Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism.

Barthlen W, Blankenstein O, Mau H, Koch M, Höhne C, Mohnike W, Eberhard T, Fuechtner F, Lorenz-Depiereux B, Mohnike K.

J Clin Endocrinol Metab. 2008 Mar;93(3):869-75. Epub 2007 Dec 11.

PMID:
18073294
49.

Height gain with combined growth hormone and gonadotropin-releasing hormone analog therapy in two pubertal siblings with a growth hormone-releasing hormone receptor mutation.

Walenkamp MJ, Pereira AM, Oostdijk W, Stokvis-Brantsma WH, Pfaeffle RW, Blankenstein O, Wit JM.

J Clin Endocrinol Metab. 2008 Jan;93(1):204-7. Epub 2007 Oct 9.

PMID:
17925337
50.

Early glibenclamide treatment in a clinical newborn with KCNJ11 gene mutation.

Däublin G, Lorenz-Depiereux B, Strom TM, Blankenstein O, Raile K.

Diabetes Care. 2007 Oct;30(10):e104. No abstract available.

PMID:
17901525

Supplemental Content

Loading ...
Support Center